U.S. Physical Therapy Inc. (USPH) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
U.S. Physical Therapy Inc. (USPH) advanced +1.47% to $86.57, trading at 87% of its 52-week range ($58.19 – $90.94). Solid 19% profit margin (12% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
U.S. Physical Therapy has delivered a mixed ride for shareholders, with the stock down 12.2% over 5 years but showing positive shorter term moves. That uneven share price record puts the focus squarely on one issue for i
U.S. Physical Therapy has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.2%. The stock now trades at $88.57, marking a 21% gain. This performance may have investors wondering h
HOUSTON, October 21, 2026--U.S. Physical Therapy, Inc. ("USPH" or the "Company") (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services,
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +16.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on USPH today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for USPH. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, U.S. Physical Therapy Inc. (USPH) ranks #146 by composite RQD confidence (64/100, grade C) and #328 by equity capitalization ($1.29B). Within this direct 5-issuer industry benchmark cohort, USPH leads on earnings valuation at 32.6x trailing P/E, while USPH leads on capital efficiency and profitability with 11.5% ROIC and 19.2% gross margin. USPH currently leads its immediate peer cohort in composite quantitative strength at 64/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| USPH
ACTIVE
U.S. Physical Therapy Inc. | C | 64/100 | 32.6x | 19.2% | 11.5% | +1.47% | $1.29B | Benchmark Subject |
| INNV InnovAge Holding Corp. | D+ | 57/100 | — | 18.0% | -10.2% | +1.54% | $1.26B | /innv-vs-usph → |
| OMDA Omada Health Inc. | D+ | 56/100 | — | 65.7% | -15.7% | +2.45% | $1.20B | /omda-vs-usph → |
| PNTG The Pennant Group Inc. | D+ | 56/100 | 50.2x | — | 11.0% | +0.76% | $1.48B | /pntg-vs-usph → |
| TDOC Teladoc Health Inc. | D+ | 56/100 | — | — | -17.0% | +26.89% | $1.59B | /tdoc-vs-usph → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), U.S. Physical Therapy Inc. (USPH) reported GAAP revenue of $781.0M (+16.3% vs. FY2024 revenue of $671.3M , and +29.1% cumulative change since FY2023) , GAAP net income of $39.6M, operating cash flow of $75.1M, and free cash flow of $75.1M (+0.2% YoY). On the balance sheet, USPH closed FY2025 with $1.20B in total assets against $152.6M in total debt (Altman Z-Score: 2.94, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $781.0M | $39.6M | $75.1M | $75.1M | $1.20B | $152.6M |
| FY2024 (FY) | 2024-12-31 | $671.3M | $31.4M | $74.9M | $74.9M | $1.17B | $142.5M |
| FY2023 (FY) | 2023-12-31 | $604.8M | $28.2M | $82.0M | $82.0M | — | — |
As of 2026-11-01, U.S. Physical Therapy Inc. (NYSE: USPH) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $86.57 (+1.47% 1D, market cap $1.29B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, USPH ranks #146 in composite RQD confidence.
Within the Health Care sector (Medical/Nursing Services), USPH carries a Roarable C (64/100 RQD), trailing P/E of 32.6x, gross margin of 19.2%, and ROIC of 11.5%. By comparison, INNV (InnovAge Holding Corp.) holds a D+ grade (57/100 RQD, P/E N/A, ROIC -10.2%, cap $1.26B) and OMDA (Omada Health Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC -15.7%, cap $1.20B). Among the 5-stock peer group, USPH leads on earnings multiple (32.6x) while USPH leads on capital efficiency (11.5% ROIC).
Per USPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000885978), U.S. Physical Therapy Inc. generated $781.0M in revenue (+16.3% YoY), $39.6M in net income, and $75.1M in free cash flow against $1.20B in total assets and $152.6M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
USPH last traded at $86.57 (+1.47% on volume of 105,198 shares), positioning the stock +4.53% above its 50-day simple moving average ($82.82) and +12.79% above its 200-day simple moving average ($76.75). Across its 52-week range of $58.19 to $90.94, USPH sits at the 86.7% percentile with a 14-day RSI of 52.3 (NEUTRAL RANGE) and an implied next-earnings move of ±6.8% ($80.68 to $92.46).
Why USPH Stock advanced +1.47% Today — RQD Quant Desk Flash. Solid 19% profit margin (12% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.